☆ 4.5 Letter

Switching from omalizumab to mepolizumab in severe asthmatics: A post hoc analysis of the RELight study

CLINICAL AND EXPERIMENTAL ALLERGY (2023)

Related references

Note: Only part of the references are listed.

Review Allergy

Biologics for severe asthma: The real-world evidence, effectiveness of switching, and prediction factors for the efficacy

Hiroyuki Nagase et al.

Summary: Biologics, such as anti-IgE, anti-IL-5, anti-IL-4/IL-13, and anti-TSLP, have been effective in the treatment of severe asthma. However, real-world research is needed to include patients who may have been excluded from clinical trials. The identification of biomarkers for predicting response to different biologics is crucial, and there is a need to evaluate the effectiveness and safety of switching biologics and discontinuation.

ALLERGOLOGY INTERNATIONAL (2023)

Add to Collection

Letter Allergy

RELIght: A two-year REal-LIfe study of mepolizumab in patients with severe eosinophilic asTHma in Greece: Evaluating the multiple components of response

Maria Kallieri et al.

ALLERGY (2022)

Add to Collection

Article Respiratory System

Switching from omalizumab to mepolizumab: real-life experience from Southern Italy

Giovanna Elisiana Carpagnano et al.

THERAPEUTIC ADVANCES IN RESPIRATORY DISEASE (2020)

Add to Collection

Article Allergy

The clinical benefit of mepolizumab replacing omalizumab in uncontrolled severe eosinophilic asthma

Kenneth R. Chapman et al.

ALLERGY (2019)

Add to Collection

Article Allergy

Efficacy of mepolizumab in patients with previous omalizumab treatment failure: Real-life observation

Diego Bagnasco et al.

ALLERGY (2019)

Add to Collection

Article Respiratory System

International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma

Kian Fan Chung et al.

EUROPEAN RESPIRATORY JOURNAL (2014)

Add to Collection

Switching from omalizumab to mepolizumab in severe asthmatics: A post hoc analysis of the RELight study

Related references

Biologics for severe asthma: The real-world evidence, effectiveness of switching, and prediction factors for the efficacy

RELIght: A two-year REal-LIfe study of mepolizumab in patients with severe eosinophilic asTHma in Greece: Evaluating the multiple components of response

Switching from omalizumab to mepolizumab: real-life experience from Southern Italy

The clinical benefit of mepolizumab replacing omalizumab in uncontrolled severe eosinophilic asthma

Efficacy of mepolizumab in patients with previous omalizumab treatment failure: Real-life observation

International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma

Export Citation

Share Paper